AGMB · AgomAb Therapeutics NV · Documents
Market Cap
$448.16M
Shares
49.25M
Volume · Oct 21
42.43K
Avg daily vol (3M)
136.3K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | Agomab Therapeutics NV dosed the first patient in the global NOV-ERA Phase 2b study of ontunisertib, expected to enroll approximately 320 adults and trigger a €7 million milestone payment to Origo Biopharma’s former shareholders. | 2026-10-13 | — | |
| 6-K | — | 2026-10-01 | — | |
| 6-K | — | 2026-09-14 | — | |
| 6-K | — | 2026-09-11 | — | |
| 6-K | — | 2026-08-10 | — | |
| 6-K | — | 2026-08-06 | — | |
| 6-K | — | 2026-06-23 | — | |
| 6-K | — | 2026-05-27 | — | |
| 6-K | — | 2026-04-24 | — | |
| 20-F | — | 2026-04-23 | 2025-12-31 | |
| 6-K | — | 2026-03-05 | — | |
| 6-K | — | 2026-02-09 | — | |
| F-1/A | — | 2026-01-29 | — | |
| F-1 | — | 2026-01-16 | — |
Showing 1–14 of 14 filings